Crossref
Concerns That May Limit the Utility of Zuranolone
JAMA · 2024
DOI: 10.1001/jama.2023.26103 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, 2024. Verfasst von Vinay Prasad und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of California San Francisco. Hauptthemen laut MEDLINE: Drug Approval, Antidepressive Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
This Viewpoint discusses the evidence base of the US Food and Drug Administration approval of zuranolone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Drug ApprovalAntidepressive AgentsPregnanesPyrazolesUnited StatesUnited States Food and Drug AdministrationPregnanolone
Substanzen
PregnanesPyrazolesAntidepressive AgentszuranolonePregnanolone
Autor:innen und Institutionen
- University of California San Francisco.
- Icahn School of Medicine at Mount Sinai, New York, New York.
Zitieren
APA
Prasad, V., & Allely, D. (2024). Concerns That May Limit the Utility of Zuranolone. JAMA. https://doi.org/10.1001/jama.2023.26103
Vancouver
Prasad V, Allely D. Concerns That May Limit the Utility of Zuranolone. JAMA. 2024. doi:10.1001/jama.2023.26103
BibTeX
@article{Prasad2024,
author = {Prasad, Vinay and Allely, David},
title = {Concerns That May Limit the Utility of Zuranolone},
journal = {JAMA},
year = {2024},
doi = {10.1001/jama.2023.26103}
}
EUVIMED